In this conversation, Kim Laipple and Leo discuss the intricacies of innovation in the dental industry, exploring Leo's journey from advertising to becoming an executive in dental product development. They delve into the importance of clinician feedback, the challenges of introducing new products, and the role of experience in understanding user needs. Leo shares insights on becoming an inventor and the excitement of launching innovative products at Premier Dental, emphasizing the need for a deep understanding of clinician workflows to drive successful adoption of new technologies. In this conversation, Kim Laipple and Leo discuss the latest innovations in dentistry, focusing on antimicrobial solutions and the challenges of brand perception in the dental market. They explore lessons learned from product launch failures, the transition from large organizations to startups, and the importance of curiosity and humility in career transitions. The discussion also touches on the future of dentistry, emphasizing the need for global access to dental care and the role of smart materials in improving patient outcomes.TakeawaysInnovation in dentistry is often misunderstood and underutilized.
Clinician feedback is crucial for successful product development.
Experience in the field can significantly enhance product innovation.
Understanding user needs is more important than personal opinions.
The journey from idea to adoption involves many complexities.
Effective questioning can uncover valuable insights from clinicians.
Resistance to change is common among clinicians; understanding their perspective is key.
Product development must consider multiple aspects, including workflow and pricing.
Collaboration with technical teams is essential for successful innovation.
Creating a culture of innovation attracts talent and drives growth. Antimicrobial solutions are crucial for dental restorations.
Market research is essential for product validation.
Brand perception can hinder innovation in established companies.
Learning from product failures is vital for future success.
Transitioning to a smaller organization requires unlearning previous habits.
Curiosity and humility are key traits for career growth.
Global access to dental care is a pressing issue.
Smart materials are the future of dental products.
Innovation in dentistry is often unseen by the public.
Understanding market needs is critical for product adoption.

Key Points

Keywords

dentistry, innovation, product development, clinician feedback, dental technology, dental products, user experience, dental industry, dental health care, dental innovation dentistry, antimicrobial solutions, product launch, brand perception, career transition, dental innovation, market challenges, dental materials, global access, smart materials

Episode 3: Building Biotech in a Tough Market | Funding, Cancer Resistance & Entrepreneurship with Anton Xavier

What does it really take to build and lead biotech companies in a challenging funding environment? In this episode of Inside the Industry, host Kim Laipple sits down with Anton Xavier, scientist, biotech entrepreneur, venture mentor, and CEO of iNanoRNA Therapeutics and K9 Biotech, for an in-depth conversation about the realities of building early-stage biotech companies.

A major focus of the discussion is cancer resistance and tumor heterogeneity. Anton explains why targeting cancer through a single mechanism can lead to treatment resistance and describes the scientific rationale behind a multimodal microRNA approach designed to target multiple mechanisms of cancer biology through a single therapeutic strategy.
Looking ahead, Anton shares his five-year vision for both organizations, including clinical development, Phase II opportunities, licensing deals, M&A, and potential public-market milestones.

In this episode:

▪️ Building and leading early-stage biotech companies
▪️ Biotech funding and venture capital
▪️ The changing biotech investment environment
▪️ Lessons from Pfizer and big pharma
▪️ Go/no-go decisions in drug development
▪️ Translational science and commercialization
▪️ Cancer resistance and tumor heterogeneity
▪️ Multimodal microRNA therapeutics
▪️ Oncology and infectious disease
▪️ Animal health and human health innovation
▪️ African swine fever and unmet medical needs
▪️ Proof-of-concept studies in animal health
▪️ SBIR and non-dilutive funding
▪️ Clinical PIs and biotech development
▪️ Licensing, M&A and the future of biotech

📙 Connect With Us:
▪️Follow Kimberly Laipple on LinkedIn: https://www.linkedin.com/in/kimberlylaipple/
▪️Scientific Search on LinkedIn: https://www.linkedin.com/company/scientific-search/
▪️About Scientific Search: https://scientificsearch.com/
▪️Follow Scientific Search on Facebook: https://www.facebook.com/scientificsearch/
▪️Follow Scientific Search on X (Twitter): https://x.com/scientificsch

📙 Connect With Anton:
▪️Follow Anton Xavier on LinkedIn: linkedin.com/in/anton-xavier-3809b71b
▪️iNanoRNA Therapeutics on LinkedIn: https://www.linkedin.com/company/inanorna-therapeutics/
▪️K9 Biotech on LinkedIn: https://www.linkedin.com/company/k9-biotech/

📙 𝐃𝐈𝐒𝐂𝐋𝐀𝐈𝐌𝐄𝐑:
The views expressed by guests are their own and are shared for educational and informational purposes only.

📙 𝐂𝐎𝐏𝐘𝐑𝐈𝐆𝐇𝐓 𝐍𝐎𝐓𝐈𝐂𝐄:
© Inside the Industry with Kim Laipple. All rights reserved. Unauthorized use, reproduction, or distribution of this content is prohibited.

Episode 2: Why Great Science Doesn’t Sell Itself | Biotech Marketing, AI & Scientific Communication

Why doesn’t great science always sell itself?

In Episode 2 of Inside the Industry, Kim Laipple sits down with Jason, Founder & CEO of Sumba Scientific, to explore the intersection of science, business, marketing, commercialization, and AI in the life sciences industry.

Jason shares his journey from working as a biochemist and cancer drug discovery researcher to building a marketing agency focused specifically on biotech and life science companies.

Together, Kim and Jason examine why having strong scientific technology isn't enough to guarantee commercial success—and why understanding your customers, their problems, and the value of your solution is essential.

📙 In This Episode:
✔ Why great science doesn't automatically sell itself
✔ Jason's journey from bench science to biotech marketing
✔ Transitioning from scientific research to sales and strategy
✔ How biotech companies can identify ideal customers
✔ Customer discovery and product-market fit
✔ Marketing problems vs. product and sales problems
✔ How scientific data builds credibility and trust
✔ Why brand awareness alone doesn't generate revenue
✔ Sales vs. marketing in early-stage biotech companies
✔ How customer applications shape marketing messaging
✔ The impact of AI on biotech and life science marketing
✔ AI-generated content vs. human creativity
✔ Why AI answers should be "trust but verify"
✔ Transparency and scientific data validation
✔ Misinformation and trust in science
✔ The future of life science marketing and commercialization

Whether you're a scientist, biotech founder, life science entrepreneur, marketer, sales professional, or innovation leader, this conversation offers practical insights into turning complex scientific innovation into clear value, stronger customer relationships, and commercial success.

What does it really take to bring breakthrough therapies from the lab to patients?

In the premiere episode of Inside the Industry, Kim Laipple sits down with Patrick Doyle, CEO of Trio Pharmaceuticals, to discuss the realities of biotech leadership, drug development, fundraising, and innovation.

With more than 25 years of experience spanning startups and global pharmaceutical leaders including Novo Nordisk and Roche, Patrick shares the pivotal moments that shaped his career, lessons learned through both success and failure, and why the best biotech leaders let data—not emotion—guide critical decisions.

The conversation explores the challenges of raising capital in today's market, the importance of experienced leadership teams, Trio's innovative Trailbody™ platform for targeted cancer therapies, and emerging technologies such as artificial intelligence and synthetic organ development that could reshape the future of medicine.

Whether you're a biotech executive, scientist, investor, entrepreneur, or simply passionate about healthcare innovation, this episode offers valuable insights into the people and decisions driving the life sciences industry forward.

• Patrick's journey from scientist to biotech CEO
• Leadership lessons from Novo Nordisk and Roche
• Navigating setbacks in drug development
• What investors look for in biotech companies
• How Trio's Trailbody™ platform targets cancer cells
• Why "kill early" is a critical biotech philosophy
• AI's role in drug discovery and development
• The future of regenerative medicine and synthetic organs
• Building resilient teams and making data-driven decisions

Patrick Doyle is the CEO of Trio Pharmaceuticals. Throughout his career, he has helped build and lead multiple biotechnology companies, raised more than $300 million across seven ventures, and contributed to four successful acquisitions. Prior to Trio, he served in executive leadership roles at K Bio, Stellexis Bioscience, Novo Nordisk, and Roche.

Trio Pharmaceuticals: https://www.triopharmaceuticals.com

Patrick Doyle: https://www.linkedin.com/in/pj-doyle/

Scientific Search: https://www.scientificsearch.com

If you enjoyed this episode, be sure to subscribe, leave a review, and share it with colleagues in biotech, pharmaceuticals, and healthcare innovation.

#InsideTheIndustry #Biotech #LifeSciences #Pharmaceuticals #DrugDevelopment #Biotechnology #Leadership #CancerResearch #HealthcareInnovation #ScientificSearch